RT Journal Article ID 4154be4b79d53b98 A1 Gao, Lingbao A1 Yuan, Keyu A1 Ding, Wei A1 Lin, Mei T1 Notch Signaling: A Potential Therapeutic Target for Hematologic Malignancies JF Critical Reviews™ in Eukaryotic Gene Expression JO CRE YR 2016 FD 2016-09-15 VO 26 IS 3 SP 239 OP 246 K1 Notch signaling K1 hematological malignancies K1 γ-secretase inhibitors K1 monoclonal antibodies K1 Zmizl AB Notch signaling is a well-conserved cell-fate determining factor in embryo development, and the dyregulation of this signaling is frequently observed in many types of cancers, including hematological malignancies. In this review, we briefly describe the Notch signaling pathway, and we primarily focus on the relationship between Notch and hematological malignancies. We also discuss the clinical development of promising agents including γ-secretase inhibitors (GSIs) and monoclonal antibodies (mAbs). Complete response has been observed among patients with T-cell acute lymphoblastic leukemia (T-ALL) when treated with GSIs. Furthermore, a recent study has suggested that targeting Zmiz1, a direct, selective cofactor of Notch1, rather than targeting Notch directly, maybe helpful to reduce the current target-related toxicities. Taken together, we summarize the role of Notch signaling in hematological malignancies and discuss the treatment strategies for these diseases through targeting Notch signaling. PB Begell House LK https://www.dl.begellhouse.com/journals/6dbf508d3b17c437,71665d545a4ae331,4154be4b79d53b98.html